These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 21404630

  • 1. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
    Okamoto Y.
    Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
    [Abstract] [Full Text] [Related]

  • 2. OCD: where the serotonin selectivity story begins.
    Pigott TA.
    J Clin Psychiatry; 1996; 57 Suppl 6():11-20. PubMed ID: 8647793
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF.
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder.
    Goddard AW, Shekhar A, Whiteman AF, McDougle CJ.
    Drug Discov Today; 2008 Apr; 13(7-8):325-32. PubMed ID: 18405845
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors.
    Kim CH, Cheon KA, Koo MS, Ryu YH, Lee JD, Chang JW, Lee HS.
    Neuropsychobiology; 2007 Apr; 55(3-4):156-62. PubMed ID: 17657168
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T.
    Seishin Shinkeigaku Zasshi; 2011 Apr; 113(10):1016-25. PubMed ID: 22187889
    [Abstract] [Full Text] [Related]

  • 15. The pathogenesis and treatment of obsessive-compulsive disorder.
    Dolberg OT, Iancu I, Sasson Y, Zohar J.
    Clin Neuropharmacol; 1996 Apr; 19(2):129-47. PubMed ID: 8777767
    [Abstract] [Full Text] [Related]

  • 16. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
    Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn CG, Petkova E.
    Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
    [Abstract] [Full Text] [Related]

  • 17. Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder.
    Koo MS, Kim EJ, Roh D, Kim CH.
    Expert Rev Neurother; 2010 Feb; 10(2):275-90. PubMed ID: 20136383
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.
    Fineberg NA, Reghunandanan S, Brown A, Pampaloni I.
    Aust N Z J Psychiatry; 2013 Feb; 47(2):121-41. PubMed ID: 23125399
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.